The majority of GIST cases (80%) harbor mutations in exon 11 of the KIT gene, which have a robust response to treatment with the kinase inhibitor imatinib [5], followed by mutations in the PDGFRA gene (10%), often associated with low-risk GIST [6]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.